Transarterial chemoembolization (TACE) in hepatocellular carcinoma: Technique, indication and results;Transarterielle chemoembolisation (TACE) des hepatozellulären karzinoms: Technik, indikationsstellung und ergebnisse

RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren

Volumn 179, Issue 11, 2007, Pages 1113-1126

  Vogl, Thomas J ^a   Zangos, S ^a   Balzer, J O ^a   Nabil, M ^a   Rao, P ^a   Eichler, K ^a   Bechstein, W O ^a   Zeuzem, S ^a   Abdelkader, A ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Hepatic arteries; Interventional procedures; Transarterial chemoembolization

Indexed keywords

ADARUBICIN; ANTINEOPLASTIC AGENT; CARBOPLASTIN; CIRDIAMINEDICHOROPLATIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; MITOMYCIN; PHOSPHATIDYLCHOLINE; TAMOXIFEN; UNCLASSIFIED DRUG; ZINOSTATIN;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; DRUG RESPONSE; HUMAN; LIVER CELL CARCINOMA; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; GELATIN SPONGE, ABSORBABLE; HUMANS; INJECTIONS, INTRA-ARTERIAL; IODIZED OIL; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MITOMYCIN; PALLIATIVE CARE;

EID: 36348942393     PISSN: 14389029     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-963285     Document Type: Review

References (109)

1. Poon RTP, Fan ST, Wong J. Risk factors, prevention and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000; 232: 10-24
2. Bruix J, Castells A, Bosch J et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996; 111: 1018-1022
3. Ramsey DE, Kernagis LY, Soulen MC et al. Chemoembolization of Hepatocellular Carcinoma. JVIR 2002; 13: 211-221
4. Pugh RNH, Murray-Lyon IM, Dawson JL et al. Transection of the oesophagus for bleeding of oesophageal varices. Br J Surg 1973; 60: 646-649
5. Okuda K, Ohtsuki T, Obata H et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer 1985; 56: 918-928
6. The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998; 28: 751-755
7. Ueno K, Miyazono N, Inoue H et al. Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma: evaluation of three kinds of regimens and analysis of prognostic factors. Cancer 2000; 88: 1574-1581
8. Charnsangavej C. Chemoembolization of liver tumors. Semin Invest Radiol 1993; 10: 150-160
9. Lubienski A, Bitsch RG, Schemmer P et al. Langzeitergebnisse der interventionellen Therapie von großen, inoperablen hepatozellulären Karzinomen (HCC): signifikanter Überlebensvorteil von transarterieller Chemoembolisation (TACE) und perkutaner Ethanolinjektion (PEI) gegenüber der TACE-Monotherapie. Fortschr Röntgenstr 2004; 176: 1794-1802
10. Zangos S, Gille T, Eichler K et al. Transarterielle Chemoembolisation bei hepatozellulären Karzinomen: Technik, Indikationsstellung, Ergebnisse. Radiologe 2001; 41: 906-914
11. Lee K, Sung K, Lee D et al. Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: Anatomic and Hemodynamic Considerations in the Hepatic Artery and Portal Vein. RadioGraphics 2002; 22: 1077-1091
12. Raoul JL, Guyader D, Bretagne JF et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997; 26: 1156-1161
13. Matsuo N, Uchida H, Sakaguchi H et al. Optimal lipiodol volume in transcatheter arterial chemoembolotherapy for hepatocellular carcinoma: study based on lipiodol accumulation patterns and histopatho logic findings. Semin Oncol 1997; 24: 61-70
14. Nakao N, Uchida H, Kamino K et al. Determination of the optimum dose level of lipiodol in transcatheter arterial embolization of primary hepatocellular carcinoma based on retrospective multivariate analysis. Cardiovasc Intervent Radiol 1994; 17: 76
15. Gerhards A, Mildenberger P, Herber S et al. Möglicher Nutzen und Auswirkung einer Lipiodolmarkierung auf die Histologie beim hepatozellulären Karzinom. Fortschr Röntgenstr 2005; 177: 1380-1386
16. Hong-Yan C, Yi S, Xiang W et al. Adjustment of lipiodol dose according to tumor blood supply during transcatheter arterial chemoembolization for large hepatocellular carcinoma by multidetector helical CT. World J Gastroenterol 2004; 10: 2753-2755
17. Vogl TJ, Trapp M, Schroeder H et al. Transarterial chemoembolization for hepatocellular carcinoma: volumetric and morphologic CT criteria for assessment of prognosis and therapeutic success-results from a liver transplantation center. Radiology 2000; 214: 349-357
18. Basile A, Rand T, Lomoschitz F et al. Trisacryl gelatin microspheres versus polyvinyl alcohol particles in the preoperative embolization of bone Neoplasms. Cardiovasc Intervent Radiol 2004; 27: 495-502
19. Llovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomized controlled trial. Lancet 2002; 359: 1734-1739
20. Rand T, Loewe C, Schoder M et al. Arterial Embolization of Unresectable Hepatocellular Carcinoma with Use of Microspheres, Lipiodol, and Cyanoacrylate. Cardiovasc Intervent Radiol 2005; 28: 313-318
21. Gunji T, Kawauchi N, Akahane M et al. Treatment of unresectable hepatocellular carcinoma less than 2 centimeters by transcatheter arterial chemoembolization with autologous blood clot. J Clin Gastroenterol 2003; 36: 347-51
22. Kwok P, Lam TW, Chan S et al. A randomized clinical trial comparing autologous blood clot and gelfoam in transarterial chemoembolization for inoperable hepatocellular carcinoma. J Hepatol 2000; 32: 955-964
23. Lewis AL, Gonzalez MV, Lloyd AW et al. DC Bead: In Vitro Characterization of a Drug-delivery Device for Transarterial Chemoembolization. JVIR 2006; 17: 335-342
24. Solomon B, Soulen MC, Baum RA et al. Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol: prospective evaluation of response and survival in a U. S. population. JVIR 1999; 10: 793-798
25. Konno T, Maeda H, Iwai K et al. Effect of arterial adminisrration of high-molecular-wight anticancer agent SMANCS with lipid lymphography agent on hepatoma: a preliminary report. Eur J Cancer Clin Oncol 1983; 19: 1053-1065
26. Horiguchil Y, Itohl M, Takagawa H et al. Chemotherapy and Pharmacology Assessment of chemoembolization therapy for primary liver cancer using a stabilized A driamycin-lipiodol suspension. Cancer Chemother Pharmacol 1992; 31: 60-64
27. Takayusa K, Shima Y, Muramatsu Y et al. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology 1987; 163: 345
28. Nakamura N, Hashimoto T, Oi H et al. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1989; 170: 783
29. Pelletier G, Ducreux M, Gay F et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. J Hepatol 1998; 29: 129-134
30. Kamada K, Nakanishi T, Kitamoto M et al. Long-term Prognosis of Patients Undergoing Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Comparison of Cisplatin Lipiodol Suspension and Doxorubicin Hydrochloride Emulsion. J Vasc Interv Radiol 2001; 12: 847-854
31. Cejna M. Chemoembolisation bei hepatozellulärem Karzinom (HCC). J Gastroenterol Hepatol 2006; 5: 12-16
32. Sakamoto I, Nobuya A, Nagaoki K et al. Complications associated with transcatheter arterial embolization for hepatic tumors. Radiographics 1998; 18: 605-619
33. Leung D, Goin J, Sickles C et al. Determinants of Postembolization Syndrome after Hepatic Chemoembolization. J Vasc Interv Radiol 2001; 12: 321-326
34. Chung JW, Park JH, Han JK et al. Hepatic tumors: predisposing factors for complications of transarterial oily chemoembolization. Radiology 1996; 198: 33-40
35. Patel NH, Hahn D, Rapp S et al. Hepatic artery embolization: factors predisposing to postembolization pain and nausea. J Vasc Interv Radiol 2000; 11: 453-460
36. Miyoshi S, Minami Y, Kawata S et al. Changes in hepatic functional reserve after transcatheter embolization of hepatocellular carcinoma. Assessment by maximal removal rate of indocyanine green. J Hepatol 1988; 6: 332-336
37. Huang YH, Chen CH, Chang TT et al. The role of transcatheter arterial embolization in patients with resectable hepatocellular carcinoma: a nation-wide, multi-center study. Liver Int 2004; 24: 419-24
38. Huppert PE, Lauchart W, Duda SH et al. Chemoembolisation des hepatozellulären Karzioms: Welche Faktoren bestimmen Therapieansprechen und Überleben? Fortschr Röntgenstr 2004; 176: 375-385
39. Uraki J, Yamakado K, Nakatsuka A et al. Transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma invading the portal veins: therapeutic effects and prognostic factors. Eur J Radiol 2004; 51: 12-18
40. Yuen MF, Chan AO, Wong BC et al. Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B: results of a comparative study in 96 Chinese patients. Am J Gastroenterol 2003; 98: 1181-1185
41. Grieco A, Marcoccia S, Miele L et al. Transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma in cirrhotics: functional hepatic reserve and survival. Hepatogastroenterology 2003; 50: 207-212
42. El Khaddari S, Gaudin JL, Abidi H et al. Chemoembolization in hepatocellular carcinoma: multivariate analysis of survival prognostic factors after the first session. Gastroenterol Clin Biol 2002; 26: 728-734
43. Ikeda K, Kumada H, Saitoh S et al. Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. Cancer 1991; 68: 2150-2154
44. Majno PE, Adam R, Bismuth H et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997; 226: 688-701
45. Sugo H, Futagawa S, Beppu T et al. Role of preoperative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma: relation between postoperative course and the pattern of tumor recurrence. World J Surg 2003; 27: 1295-1299
46. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699
47. Llovet JM, Mas X, Aponte JJ et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 2002; 50: 123-128
48. Herber S, Schneider J, Brecher B et al. TACE: Therapie des HCC vor Lebertransplantation - Erfahrungen. Fortschr Röntgenstr 2005; 177: 681-690
49. Yao FY, Ferrell L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-1403
50. Richard III HM, Silberzweig JE, Mitty HA et al. Hepatic arterial complications in liver transplant recipients treated with pretransplantation chemoembolization for hepatocellular carcinoma. Radiology 2000; 214: 775
51. Sotiropoulos GC, Malago M, Molmenti E et al. Efficacy of transarterial chemoembolization prior to liver transplantation for hepatocellular carcinoma as found in pathology. Hepatogastroenterology 2005; 52: 329-332
52. De Carlis L, Giacomoni A, Lauterio A et al. Liver transplantation for hepatocellular cancer: should the current indication criteria be changed? Transpl Int 2003; 16: 115-122
53. Lesurtel M, Mullhaupt B, Pestalozzi BC et al. Transarterial Chemoembolization as a Bridge to Liver Transplantation for Hepatocellular Carcinoma: An Evidence-based Analysis. American Journal of Transplantation 2006; 6: 2644-2650
54. Omata M, Tateishi R, Haruhiko Y et al. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: ethanol injection therapy and radiofrequency ablation. Gastroenterology 2004; 127: 159-166
55. Tanaka K, Okazaki H, Nakamura S et al. Hepatocellular carcinoma: treatment with a combination therapy of transcatheter arterial embolization and percutaneous ethanol injection. Radiology 1991; 179: 713-717
56. Jansen MC, van Hillegersberg R, Chamuleau RA et al. Outcome of regional and local ablative therapies for hepatocellular carcinoma: a collective review. Eur J Surg Oncol 2005; 31: 331-347
57. Koda M, Murawaki Y, Oyama K et al. Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma. Cancer 2001; 92: 1516-1524
58. Becker G, Soezgen T, Olschewski M et al. Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. World J Gastroenterol 2005; 11: 6104-6109
59. Bartolozzi C, Lencioni R, Caramella D et al. Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology 1995; 197: 812-818
60. Buscarini E, Savoia A, Brambilla G et al. Radiofrequency thermal ablation of liver tumors. Eur Radiol 2005; 15: 884-894
61. Clasen S, Pereira PL. Radiofrequenzablation von Lungentumoren. Fortschr Röntgenstr 2006; 178: 852-861
62. Ahrar K, Newmann RA, Pang J et al. Dr. Gary J. Becker Young Investigator Award: relative thermosensitivity of cytotoxic drugs used in transcatheter arterial chemoembolization. J Vascular Interv Radiol 2004; 15: 901-905
63. Veltri A, Moretto P, Doriguzzi A et al. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol 2006; 16: 661-669
64. Hansler J, Frieser M, Schaber S et al. Radiofrequency ablation of hepatocellular carcinoma with a saline solution perfusion device: a pilot study. J Vasc Interv Radiol 2003; 14: 575-580
65. Yamakado K, Nakatsuka A, Ohmori S et al. Radiofrequency ablation combined with chemoembolization in hepatocellular carcinoma: treatment response based on tumor size and morphology. J Vasc Interv Radiol 2002; 13: 1225-1232
66. Kühl H, Stattaus J, Kühl B et al. Radiofrequenzablation von malignen Lebertumoren: Erlaubt ein volumetrischer Nekrose-/Tumor-Quotient eine Vorhersage zur lokalen Tumorkontrolle? Fortschr Röntgenstr 2006; 178: 1243-1249
67. Porrett PM, Peterman H. Lack of benefit of pretranspant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. J Vasc Interv Radiol 2006; 17: 1070
68. Vogl TJ, Straub R, Eichler K et al. Malignant liver tumors treated with MR imaging-guided laser-induced thermotherapy: experience with complications in 899 patients (2,520 lesions). Radiology 2002; 225: 367-377
69. Vogl TJ, Mack M, Straub R et al. Thermische Ablation von Lebermetastasen: Aktueller Stand und Perspektiven. Radiologe 2001; 41: 49-55
70. Pacella CM, Bizzarri G, Cecconi P et al. Hepatocellular carcinoma: long-term results of combined treatment with laser thermal ablation and transcatheter arterial chemoembolization. Radiology 2001; 219: 669-678
71. Zangos S, Eichler K, Balzer JO et al. Large-sized hepatocelullar carcinoma (HCC): Neoadjuvant treatment protocol with repetitive transarterial chemoembolization (TACE) before percutaneous MR-guided laser induced thermotherapy (LITT). Eur Radiol 8.8.2006 [Epub ahead of print]
72. Miyamoto M, Sudo T, Kuyama T. Spontaneous rupture of hepatocellular carcinoma: a review of 172 Japanese cases. Am J Gastroenterol 1991; 86: 67-71
73. Liu CL, Fan ST, Lo CM et al. Management of Spontaneous Rupture of Hepatocellular Carcinoma: Single-Center Experience. J Clin Oncol 2001; 19: 3725-3732
74. Ong GB, Taw JL. Spontaneous rupture of hepatocellular carcinoma. BMJ 1972; 4: 146-149
75. Ngan H, Tso WK, Lai CL et al. The role of hepatic arterial embolization in the treatment of spontaneous rupture of hepatocellular carcinoma. Clin Radiol 1998; 53: 338-41
76. Kulik LM, Atassi B, Van Hosbeeck L et al. Yttrium-90 Microspheres (TheraSphere®) Treatment of Unresectable Hepatocellular Carcinoma: Downstaging to Resection, RFA and Bridge to Transplantation. J Surg Oncol 2006; 94: 572-586
77. Huang YH, Wu JC, Chen SC et al. Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter. Aliment Pharmacol Ther 2006; 23: 129-135
78. Liem MS, Poon RT, Lo CM et al. Outcome of transarterial chemoembolization in patients with inoperable hepatocellular carcinoma eligible for radiofrequency ablation. World J Gastroenterol 2005; 11: 4465-4471
79. Chung YH. A strategy for early detection of recurrent hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization. Intervirology 2005; 48: 46-51
80. Greten TF, Papendorf F, Bleck JS et al. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer 2005; 92: 1862-1868
81. Sumie S, Yamashita F, Ando E et al. Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization. Am J Roentgenol 2003; 181: 1327-1334
82. Maeda S, Shibata J, Fujiyama S et al. Long-term follow-up of hepatic arterial chemoembolization with cisplatin suspended in iodized oil for hepatocellular carcinoma. Hepatogastroenterology 2003; 50: 809-813
83. Junji F, Hiroshi I, Mitsuo S et al. Pilot Study of Transcatheter Arterial Chemoemblization with Degradable Starch Microspheres in Patients with Hepatocellular Carcinoma. Am J Clin Oncol 2003; 26: 159-164
84. O'Suilleabhain CB, Poon RTB, Yong JL et al. Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. British Journal of Surgery 2003; 90: 325-331
85. Ebied OM, Federle MP, Carr BI et al. Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer 2003; 97: 1042-1050
86. Saccheri S, Lovaria A, Sangiovanni A et al. Segmental transcatheter arterial chemoembolization treatment in patients with cirrhosis and inoperable hepatocellular carcinomas. J Vasc Interv Radiol 2002; 13: 995-999
87. Achenbach T, Seifert JK, Pitton MB et al. Chemoembolization for primary liver cancer. Eur J Surg Oncol 2002; 28: 37-41
88. Fan J, Tang ZY, Yu YQ et al. Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma. Dig Surg 1998; 15: 674-678
89. Poyanli A, Rozanes I, Acunas B et al. Palliative treatment of hepatocellular carcinoma by chemoembolization. Acta Radiol 2001; 42: 602-607
90. Takayasu K, Arii S, Matsuo N et al. Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. Am J Roentgenol 2000; 175: 699-704
91. Liado L, Virgill J, Figueras J et al. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer 2000; 88: 50-57
92. Savastano S, Miotto D, Casarrubea G et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with Child's grade A or B cirrhosis: a multivariate analysis of prognostic factors. J Clin Gastroenterol 1999; 28: 334-340
93. Shah SR, Riordan SM, Karani J et al. Tumor ablation and hepatic decompensation rates in multi-agent chemoembolization of hepatocellular carcinoma. QJM 1998; 91: 821-828
94. Carr B. Hepatic artery chemoembolization for advanced stage HCC: experience of 650 patients. Hepatogastroenterol 2002; 49: 79-86
95. Ren ZG, Lin ZY, Xia JL et al. Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: a retrospective control study. World J Gastroenterol 2004; 10: 2791-2794
96. Ren Z, Lin Z, Ye S. Transcatheter arterial chemoembolization for postoperative residual tumor of hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi 2001; 23: 332-334
97. Lin Z, Ren Z, Xia J. Appraisal of postoperative transcatheter arterial chemoembolization (TACE) for prevention and treatment of hepatocellular carcinoma recurrence. Zhonghua Zhong Liu Za Zhi 2000; 22: 315-317
98. Zhang Z, Liu Q, He J et al. The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcinoma. Cancer 2000; 89: 2606-2612
99. Gerunda GE, Neri D, Merenda R et al. Role of transarterial chemoembolization before liver resection for hepatocellular carcinolma. Liver Transpl 2000; 6: 619-626
100. Chen XM, Luo PF, Lin HH et al. Long-term result of combination of transcatheter arterial chemoembolization and percutaneous ethanol injection for treatment of hepatocellular carcinoma. Ai Zheng 2004; 23: 829-832
101. Huo TI, Huang YH, Wu JC et al. Sequential transarterial chemoembolization and percutaneous acetic acid injection therapy versus repeated percutaneous acetic acid injection for unresectable hepatocellular carcinoma: a prospective study. Ann Oncol 2003; 14: 1648-1653
102. Li YH, Wang CS, Liao LY et al. Long-term survival of Taiwanese patients with hepatocellular carcinoma after combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection. J Formos Med Assoc 2003; 102: 141-146
103. Kamada K, Kitamoto M, Aikata H et al. Combination of transcatheter arterial chemoembolization using cisplatin-lipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinoma. Am J Surg 2002; 184: 284-290
104. Li C, Shi Z, Hao Y. Combined percutaneous ethanol injection through liver puncture and transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi 2001; 23: 490-492
105. Dohmen K, Shirahama M, Shigematsu H et al. Transcatheter arterial chemoembolization therapy combined with percutaneous ethanol injection for unresectable large hepatocellular carcinoma: an evaluation of the local therapeutic effect and survival rate. Hepatogastroentereology 2001; 48: 1409-1415
106. Lencioni R, Paolicchi A, Moretti M et al. Combined transcatheter arterial chemoembolization and percutaneous ethanol injection for the treatment of large hepatocellular carcinoma: local therapeutic effect and long-term survival rate. Eur Radiol 1998; 8: 439-444
107. Tanaka K, Nakamura S, Numata K et al. The long-term efficacy of combined transcatheter arterial embolization and percutaneous ethanol injection in the treatment of patients with large hepatocellular carcinoma and cirrhosis. Cancer 1998; 82: 78-85
108. Yamakado K, Nakatsuka A, Akeboshi M et al. Combination therapy with radiofrequency ablation and transcatheter chemoembolization for the treatment of hepatocellular carcinoma: Short-term recurrences and survival. Oncol Rep 2004; 11: 105-109
109. Bloomston M, Binitie O, Fraiji E et al. Transcatheter arterial chemoembolization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy. Am Surg 2002; 68: 827-831